👤 JunBo Li

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
3991
Articles
2551
Name variants
Also published as: Xiaofeng Li, Jiajia Li, Jingwen Li, Zhaolun Li, Litao Li, Ruyi Li, Xiaocun Li, Jianyu Li, Wanxin Li, Jinsong Li, Xinzhi Li, Guanqiao Li, Ying-Lan Li, Zequn Li, Yulin Li, Shaojian Li, Guang-Xi Li, Yubo Li, Bugao Li, Mohan Li, Yan-Xue Li, Qingchao Li, Xikun Li, Enhong Li, Guobin Li, Hong-Tao Li, Xiangnan Li, Yong-Jun Li, Rongqing Li, Xihao Li, Ziming Li, Hang Li, Jing-Ming Li, Chang-Da Li, Meng-Yue Li, Yuanchang Li, DaZhuang Li, Yicun Li, Xiao-Lin Li, Jiajie Li, Zhao-Yang Li, Shunqin Li, K-L Li, Xinjia Li, Yaqiong Li, Bin Li, Yuan-hao Li, Jianhai Li, Youran Li, Peiwu Li, Yongmei Li, Changyu Li, Ran Li, Peilin Li, X Y Li, Chunshan Li, Yixiang Li, Ming Zhou Li, Ye Li, Guanglve Li, Z Li, Zili Li, Xinmei Li, Yihao Li, Liling Li, Qing Run Li, Wulan Li, Meng-Yang Li, Ziyun Li, Haoxian Li, Xiaozhao Li, Jun-Ying Li, Da-Lei Li, Xinhai Li, Yongjiang Li, Wanru Li, Jinming Li, Huihui Li, Wenhao Li, Qiankun Li, Kailong Li, Shengxu Li, Shisheng Li, Sai Li, Guangwen Li, Hua Li, Xiuli Li, Yulong Li, Dongmei Li, Ru-Hao Li, Zhi-Peng Li, Lanzhou Li, Tingsong Li, Binjun Li, Chen Li, Jiayang Li, Yawei Li, Zunjiang Li, Chao Bo Li, Minglong Li, Donghua Li, Wenzhe Li, Siming Li, Fengli Li, Song Li, Zihan Li, Hsin-Hua Li, Jin-Long Li, Hongxin Li, Dongfeng Li, You Li, Caiyu Li, Zhen-Yuan Li, Xueyang Li, Xuelin Li, Fa-Hui Li, Guangpu Li, Teng Li, Wen-Jie Li, Hegen Li, Ang Li, Zhizong Li, Lu-Yun Li, Peng Li, Shiyu Li, Bao Li, Yin Li, Cai-Hong Li, Fang Li, Jiuke Li, Miyang Li, Chen-Xi Li, Mingxu Li, Panlong Li, Changwei Li, Dejun Li, Biyu Li, Yufeng Li, Miaoxin Li, Yaoqi Li, San-Feng Li, Hu Li, Bei Li, Sha Li, W H Li, Jiaming Li, Jiyuan Li, Ya-Qiang Li, Rongkai Li, Yani Li, Xiushen Li, Xiaoqing Li, Jinlin Li, Linke Li, Shuaicheng Li, C Y Li, Thomas Li, Siting Li, Xuebiao Li, Yingyi Li, Yongnan Li, Maolin Li, Jiyang Li, Jinchen Li, Jin-Ping Li, Xuewen Li, Zhongxuan Li, R Li, Xianlong Li, Aixin Li, Linting Li, Zhong-Xin Li, Xuening Li, Enhao Li, Guang Li, Xiaoming Li, Shengliang Li, Yongli Li, Z-H Li, Baohong Li, Hujie Li, Yue-Ming Li, Shuyuan Li, Zhaohan Li, L Li, Yuanmei Li, Alexander Li, Yanwu Li, Wen-juan Li, Hualing Li, Sibing Li, Qinghe Li, Xining Li, Pilong Li, Yun-Peng Li, Zonghua Li, C X Li, Jingya Li, Huanan Li, Liqin Li, Youjun Li, Zheng-Dao Li, Miao X Li, Zhenshu Li, KeZhong Li, Heng-Zhen Li, Linying Li, Chu-Qiao Li, Fa-Hong Li, Changzheng Li, Yuhui Li, Wei Li, Wen-Ying Li, Yaokun Li, Shuanglong Li, Zhi-Gang Li, Yufan Li, Liangqian Li, Guanghui Li, Xiongfeng Li, Fei-feng Li, Letai Li, Kangli Li, Ming Li, Runwen Li, Wenbo Li, Yarong Li, Side Li, Timmy Li, S E Li, Weidong Li, Xin-Tao Li, Ruotong Li, Xiuzhen Li, Shuguang Li, Lingxi Li, Chuan-Hai Li, Qiuya Li, Jiezhen Li, Haitao Li, Tingting Li, Guanghua Li, Yufen Li, Zhongyu Li, Qin Li, Deyu Li, Zhen-Yu Li, Hansen Li, Annie Li, Wenge Li, Jinzhi Li, Xueren Li, Chun-Mei Li, Yijing Li, Kaifeng Li, Wen-Xing Li, Meng-Yao Li, Chung-I Li, Zhi-Bin Li, Xiao Li, Qintong Li, Junping Li, PeiQi Li, Naishi Li, Xiaobing Li, Liangdong Li, Xin-Ping Li, Yan Li, Han-Ni Li, Pan Li, Shengchao A Li, Jiaying Li, Jun-Jie Li, Ruonan Li, Cui-lan Li, Shuhao Li, Huiqiong Li, Ruitong Li, Guigang Li, Lucia M Li, Chunzhu Li, Suyan Li, Chengquan Li, Zexu Li, Gen-Lin Li, Dianjie Li, Zhilei Li, Junhui Li, Tiantian Li, Ya-Jun Li, Xue Cheng Li, Wenyong Li, Ding-Biao Li, Tianjun Li, Desen Li, Yansong Li, Xiying Li, Zihao Li, Weiyong Li, Xinyang Li, Fadi Li, Huawei Li, Yu-quan Li, Cui Li, Xiaoyong Li, Y L Li, Xueyi Li, Jingxiang Li, Wenxue Li, Jihua Li, Jingping Li, Zhiquan Li, Zeyu Li, Yingpu Li, Jianglin Li, Jing-Yao Li, Yan-Hua Li, Zongdi Li, Ming V Li, Shawn Shun-Cheng Li, Aowen Li, Xiao-Min Li, L K Li, Ya-Ting Li, Wan Jie Li, Aimin Li, Dongbiao Li, Tiehua Li, Keguo Li, Yuanfei Li, Longhui Li, Jing-Yi Li, Zhonghua Li, Guohong Li, Chunyi Li, Botao Li, Peiyun Li, L-Y Li, Xiuqi Li, Qinglan Li, Zhenhua Li, Zhengda Li, Haotong Li, Yue-Ting Li, Luhan Li, Da Li, Yuancong Li, Yuxiu Li, Tian Li, YiPing Li, Beibei Li, Haipeng Li, Demin Li, Chuan Li, Changhong Li, Ze-An Li, Jianmin Li, Yu Li, Minhui Li, Yvonne Li, Yiwei Li, Jiayuan Li, Xiangzhe Li, Zhichao Li, Minglun Li, Yige Li, Siguang Li, Chengqian Li, Weiye Li, Xue-Min Li, Kenneth Kai Wang Li, Dong-fei Li, Xiangchun Li, Chunlan Li, Chiyang Li, Hulun Li, Juan-Juan Li, Hailong Li, Hua-Zhong Li, Kun-Peng Li, Jiaomei Li, Haijun Li, Jing Li, Si Li, Xiangyun Li, Ji-Feng Li, Yingshuo Li, Wanqian Li, Baixing Li, Dengke Li, Zijing Li, Wentao Li, Yuchuan Li, Qingling Li, Rui-Han Li, Xuhong Li, Hongyun Li, Dong Li, Zhonggen Li, Xiong Li, Penghui Li, Xiaoxia Li, Dezhi Li, Huiting Li, Xiaolong Li, Linqing Li, Jiawei Li, Sheng-Jie Li, Defa Li, Ying-Qing Li, X L Li, Yuyan Li, Kawah Li, Xin-Jian Li, Guangxi Li, Yanhui Li, Zhenfei Li, Shupeng Li, Sha-Sha Li, Panyuan Li, Gang Li, Ziyu Li, Mengxuan Li, Hong-Wen Li, Zhuo Li, Han-Wei Li, Xiaojuan Li, Weina Li, Xiao-Hui Li, Dongnan Li, Huaiyuan Li, Rui-Fang Li, Jianzhong Li, Huaping Li, Ji-Liang Li, C H Li, Bohua Li, Bing Li, Pei-Ying Li, Huihuang Li, Shaobin Li, Yunmin Li, Yanying Li, Ronald Li, Gui Lin Li, Chenrui Li, Shi-Hong Li, Shilun Li, Xinyu Li, John Zhong Li, Song-Chao Li, Lujiao Li, Chenghong Li, Dengfeng Li, Nianfu Li, Baohua Li, N Li, Xiaotong Li, Chensheng Li, Ming-Qing Li, Yongxue Li, Bao-Shan Li, Jiao Li, Zhimei Li, Jun-Cheng Li, Yimeng Li, Jingming Li, Jinxia Li, De-Tao Li, Chunting Li, Shu Li, Julia Li, Chien-Feng Li, Huilan Li, Mei-Zhen Li, Xin-Ya Li, Zhengjie Li, Chunsheng Li, Liwei Li, Yan-Yan Li, Huijun Li, Chengyun Li, Chengjian Li, Ying-na Li, Guihua Li, Zhiyuan Li, Lijun Li, Supeng Li, Hening Li, Yiju Li, Yuanhe Li, Guangxiao Li, Fengxia Li, Peixin Li, Xueqin Li, Feng-Feng Li, Zu-Ling Li, Jialing Li, Xin Li, Yunjiu Li, Zonghong Li, Dayong Li, Ningyan Li, Lingjiang Li, Yuhan Li, Zhenghui Li, Fuyuan Li, Ailing Li, H-F Li, Chunxia Li, Chaochen Li, Zhen-Li Li, Tengyan Li, Xianlu Li, Jiaqi Li, Jiabei Li, Zhengying Li, Zhaoshui Li, Yali Li, Wenjing Li, Yu-Hui Li, Jingshu Li, Chuang Li, Jiajun Li, Can Li, Zhe Li, Han-Bo Li, Stephen Li, Shuangding Li, Zengyang Li, Kaiyuan Li, Mangmang Li, Chunyan Li, Runzhen Li, Xiaopeng Li, Xi-Hai Li, MengGe Li, Xuezhong Li, Anan Li, Luying Li, Jiajv Li, Pei-Lin Li, Xiaoquan Li, Yanxi Li, Ning Li, Ruobing Li, Wan-Xin Li, Xia Li, Yongjing Li, Meitao Li, Ziqiang Li, Huayao Li, Wen-Xi Li, Shenghao Li, Jiqing Li, Boxuan Li, Huixue Li, Hehua Li, Yucheng Li, Qingyuan Li, Yongqi Li, Fengqi Li, Zhigang Li, Yuqing Li, Guiyang Li, Guo-Qiang Li, Dujuan Li, Yanbo Li, Yuying Li, Shaofei Li, Sanqiang Li, Shaoguang Li, Hongyu Li, Min-Rui Li, Guangping Li, Shuqiang Li, Dan C Li, Huashun Li, Jinxin Li, Ganggang Li, Xinrong Li, Haoqi Li, Yayu Li, Handong Li, Huaixing Li, Yan-Nan Li, Xianglong Li, Minyue Li, Hong-Mei Li, Jing-Jing Li, Songhan Li, Jutang Li, Mengxia Li, Conglin Li, Qingli Li, Yongxiang Li, Miao Li, Songlin Li, Qilong Li, Dijie Li, Chenyu Li, Yizhe Li, Ke Li, Yan Bing Li, Jiani Li, Lianjian Li, Zhen-Hua Li, Yiliang Li, Chuan-Yun Li, Xinpeng Li, Hongxing Li, Wanyi Li, Gaoyuan Li, Youming Li, Mi Li, Qingrun Li, Dong-Yun Li, Guo Li, Jingxia Li, Xiu-Ling Li, Fuhai Li, Ruijia Li, Shuangfei Li, Yumiao Li, Fengfeng Li, Qinggang Li, Jiexi Li, Huixia Li, Kecheng Li, Xiangjun Li, Junxu Li, Xingye Li, Junya Li, Jiang Li, Huiying Li, Shengxian Li, Qingyang Li, Yuxi Li, Chenxuan Li, Xiao-Dong Li, Xinghuan Li, Zhaoping Li, Xingyu Li, Xiaolei Li, Zhenlu Li, Wenying Li, Huilong Li, Xiao-Gang Li, Honghui Li, Zhenhui Li, Cheung Li, Zhenming Li, Xuelian Li, Shu-Fen Li, Chunjun Li, Changyan Li, Mulin Jun Li, Yinghua Li, Shangjia Li, Yanjie Li, Jingjing Li, Suhong Li, Xinping Li, Siyu Li, Chaoying Li, Qiu Li, Juanjuan Li, Xiangyan Li, Guangzhen Li, Kunlun Li, Xiaoyu Li, Shiyun Li, Yaobo Li, Shiquan Li, Mei Li, Xuewang Li, Xiangdong Li, Jifang Li, Zhenjia Li, Wan Li, Manjiang Li, Zhizhong Li, Ding Yang Li, Xiaoya Li, Xiao-Li Li, Shan Li, Shitao Li, Lijia Li, Zehan Li, Chunqiong Li, Huiliang Li, Junjun Li, Chenlong Li, Shujin Li, Hui-Long Li, Zhao-Cong Li, Zhi-Wei Li, Wenxi Li, Weining Li, Wu-Jun Li, Chang-hai Li, Bin-Kui Li, Yuqiu Li, Yumao Li, Honglian Li, Xue-Yan Li, Ya-Zhou Li, Yuan-Yuan Li, Xiang-Jun Li, Hongyi Li, Chia Li, Y X Li, Yunyun Li, Zhen-Jia Li, Fu-Rong Li, Honghua Li, Lanjuan Li, Qiuxuan Li, Xiancheng Li, Man-Zhi Li, Yanmei Li, De-Jun Li, Junxian Li, Zhihua Li, Keqing Li, Shuwen Li, Danxi Li, Saijuan Li, Minqi Li, Lingjun Li, Mimi Li, Si-Xing Li, Deheng Li, Yingjie Li, Yaodong Li, Shigang Li, Yuan-Hai Li, Lujie Li, Minghao Li, Gao-Fei Li, Minle Li, Meifen Li, Yifeng Li, Le-Le Li, Huanqing Li, Ziwen Li, Yuhang Li, Yongqiu Li, Pu-Yu Li, Jianhua Li, Chanjuan Li, Nan-Nan Li, Hongming Li, Lan-Lan Li, Shuang Li, Yanchuan Li, Lingyi Li, Wanting Li, Bai-Qiang Li, Gong-Hua Li, Zhengyu Li, Chunmiao Li, Jiong-Ming Li, Yongqiang Li, Linsheng Li, Weiguang Li, Mingyao Li, Guoqing Li, Ze Li, Xiaomeng Li, R H L Li, Yuanze Li, Yunqi Li, Yuandong Li, Guisen Li, Dongyang Li, Jinglin Li, Honglong Li, Mingfang Li, Hanmei Li, Chenmeng Li, Changcheng Li, Shiyang Li, Shiyue Li, Jianing Li, Hanbo Li, Dingshan Li, Yinggao Li, Linlin Li, Xinsheng Li, Jin-Wei Li, Cheng-Tian Li, Jin-Jiang Li, Zhi-Xing Li, Chang Li, Yaxi Li, Ming-Han Li, Wei-Ming Li, Wenchao Li, Guangyan Li, Xuesong Li, Zhaosha Li, Jiwei Li, Yongzhen Li, Chun-Quan Li, Weifeng Li, Tao Li, Sichen Li, Wenhui Li, Xiankai Li, Qingsheng Li, Yaxuan Li, Liangji Li, Lixiang Li, Yuchan Li, Tian-wang Li, Jiaxi Li, Yalin Li, Jin-Liang Li, Pei-Zhi Li, You Ran Li, Xiaoqiong Li, Guanyu Li, Jinlan Li, Yixiao Li, Huizi Li, Jianping Li, Kathy H Li, Yun-Lin Li, Yadong Li, Sujing Li, Yuhua Li, Xuri Li, Wenzhuo Li, Y Li, Deqiang Li, Caixia Li, Zipeng Li, Mingyue Li, Hongli Li, Yun Li, Mengqiu Li, Ling-Ling Li, Yanfeng Li, Yaqin Li, Yu-He Li, Shasha Li, Xi Li, S-C Li, Siyi Li, Minmin Li, Manna Li, Chengwen Li, Dawei Li, Shu-Feng Li, Haojing Li, Xun Li, Ming-Jiang Li, Zhiyu Li, Sitao Li, Ziyang Li, Qian Li, Yaochen Li, Tinghua Li, Wenyang Li, Bohao Li, Zhenfen Li, Shuo Li, Wenming Li, Mingxuan Li, Si-Ying Li, Xinyi Li, Jenny J Li, Xue-zhi Li, Shuai Li, Bingsong Li, Anqi Li, Xiaonan Li, Xiaoju Li, Ting Li, Zhenyu Li, Xiang-Yu Li, Duan Li, Lei Li, Hongde Li, Fengqing Li, Na Li, Xunjia Li, Yanchang Li, Huibo Li, Ruixia Li, Nanzhen Li, Chuanfang Li, Bingjie Li, Hongxue Li, Pengsong Li, Ruotian Li, Xiaojing Li, Xinlin Li, Zong-Xue Li, En-Min Li, Chunya Li, Yan Ning Li, Honglin Li, Yu-Ying Li, Min-jun Li, Jinhua Li, Yuanheng Li, Qian-Qian Li, Chunxiao Li, Wenli Li, Shijun Li, Mengze Li, Kuan Li, Baoguang Li, Jie-Shou Li, Kaiwei Li, Zimeng Li, Mengmeng Li, W-B Li, Huangyuan Li, Lili Li, Binkui Li, Junxin Li, Yu-Sheng Li, Wei-Jun Li, Guoyan Li, Junjie Li, Fei-Lin Li, Nuomin Li, Shanglai Li, Shulin Li, Yanyan Li, Yue Li, Taibo Li, Junqin Li, Zhongcai Li, Xueying Li, Jun-Ru Li, Xiaoqi Li, Zhaobing Li, Xiucui Li, Linxin Li, Haihua Li, Yu-Lin Li, Jen-Ming Li, Shujing Li, Tsai-Kun Li, Chen-Chen Li, Hongquan Li, Chuan F Li, Mengyun Li, Mingna Li, Yanxiang Li, Lanlan Li, Moyi Li, Xiyun Li, Yi-Wen Li, Rulin Li, Shihong Li, Ya-Pei Li, Huifeng Li, Lijuan Li, Shengbin Li, Yuanhong Li, Zhongjie Li, Zhenbei Li, Jingyu Li, Xuewei Li, Long Li, Shuangshuang Li, Wenjia Li, Min-Dian Li, Xiatian Li, Hongwei Li, Ding-Jian Li, Xiao-Qiang Li, Danni Li, Yangxue Li, Chengnan Li, Chuanyin Li, Min Li, Zhenzhou Li, Yiqiang Li, Pengyang Li, Kun-Xin Li, Xiawei Li, Binglan Li, Yutong Li, Zesong Li, Xiangpan Li, Mingfei Li, Shuwei Li, Yingnan Li, Ge Li, Mingdan Li, Xihe Li, Xinzhong Li, Jianfeng Li, Chenyao Li, Jun-Yan Li, Dexiong Li, Rongsong Li, Yinxiong Li, Boru Li, Ruixue Li, Zemin Li, Jixi Li, Chris Li, Jicheng Li, Hong-Yu Li, Chuanning Li, Weijian Li, Jiafei Li, Changhui Li, Yingying Li, Gaizhi Li, Chien-Hsiu Li, Xiangcheng Li, Siqi Li, Dechao Li, Chunxing Li, Wenxia Li, Guoxiang Li, Ziru Li, Qiao-Xin Li, Shu-Fang Li, Huang Li, Qiusheng Li, Man Li, Juxue Li, Weiqin Li, Xinming Li, Huayin Li, Xiao-yu Li, Jianyi Li, Yongjun Li, Mengyang Li, Guo-Jian Li, Guowei Li, Chenglong Li, Xingya Li, Nan Li, Gongda Li, Wei-Ping Li, Yajun Li, Yipeng Li, Mingxing Li, Nanjun Li, Xin-Yu Li, Chunyu Li, P H Li, Jinwei Li, Xuhua Li, Yu-Xiang Li, Ranran Li, Long Shan Li, Suping Li, Yanze Li, Jason Li, Xiao-Feng Li, Monica M Li, Fengjuan Li, W Li, Xianlun Li, Qi Li, Hainan Li, Yutian Li, Xiaoli Li, Xiliang Li, Shuangmei Li, Ying-Bo Li, Fei Li, Xionghui Li, Duanbin Li, Maogui Li, Dan Li, Sumei Li, Hongmei Li, Peilong Li, Kang Li, Yinghao Li, Xu-Wei Li, Mengsen Li, Lirong Li, Wenhong Li, Quanpeng Li, Audrey Li, Yijian Li, Yajiao Li, Guang Y Li, Xianyong Li, Qilan Li, Shilan Li, Qiuhong Li, Zongyun Li, Xiao-Yun Li, Guang-Li Li, Cheng-Lin Li, Bang-Yan Li, Enxiao Li, Jianrui Li, Yousheng Li, Wen-Ting Li, Guohua Li, Kezhen Li, Xingxing Li, Guoping Li, Ellen Li, A Li, Simin Li, Xue-Nan Li, Yijie Li, Weiguo Li, Xiaoying Li, Suwei Li, Shengsheng Li, Shuyu D Li, Jiandong Li, Ruiwen Li, Fangyong Li, Hong Li, Binru Li, Yuqi Li, Zihua Li, Yuchao Li, Hanlu Li, Xue-Peng Li, Jianang Li, Qing Li, Jiaping Li, Sheng-Tien Li, Yazhou Li, Shihao Li, Jun-Ling Li, Caesar Z Li, Feng Li, Weiyang Li, Lang Li, Peihong Li, Jin-Mei Li, Lisha Li, Feifei Li, Kejuan Li, Qinghong Li, Qiqiong Li, Cuicui Li, Xinxiu Li, Kaibo Li, Chongyi Li, Yi-Ying Li, Hanbing Li, Meng-Hua Li, Shaodan Li, Yongzheng Li, J T Li, Da-Hong Li, Xiao-mei Li, Jiejie Li, Ruihuan Li, Xiangwei Li, Baiqiang Li, Ziliang Li, Yaoyao Li, Mo Li, Yueguo Li, Zheng Li, Ming-Hao Li, Donghe Li, Congfa Li, Wenrui Li, Hongsen Li, Yong Li, Xiuling Li, Menghua Li, Jingqi Li, Ka Li, Kaixin Li, Fuping Li, Zhiyong Li, Jianbo Li, Xing-Wang Li, Xiao-Kang Li, Chong Li, Hanqi Li, Fugen Li, Yangyang Li, Yuwei Li, Dongfang Li, Xiaochen Li, Zizhuo Li, Zhuorong Li, X-H Li, Xianrui Li, Lan-Juan Li, Dong Sheng Li, Zhigao Li, Chenlin Li, Zihui Li, Xiaoxiao Li, Guoli Li, Le-Ying Li, Pengcui Li, Huanqiu Li, Xiaoman Li, Bing-Heng Li, Zhan Li, Weisong Li, Xinglong Li, Xiaohong Li, Xiaozhen Li, Yuan Hao Li, Jianchun Li, Wenxiang Li, Zhaoliang Li, Guo-Ping Li, Zhiyang Li, Cunxi Li, Jinhui Li, Zhifei Li, Ying Li, Yanshu Li, Jianlin Li, Yuanyou Li, Chongyang Li, Yumin Li, Wanyan Li, Longyu Li, Jinku Li, Guiying Li, X B Li, Changgui Li, Zhisheng Li, Cuiling Li, Xuekun Li, Yuguang Li, Wenke Li, Jiayi Li, Jianguo Li, En Li, Ximei Li, Shaoyong Li, Kai-Wen Li, Suwen Li, Peihua Li, Chang-Ping Li, Guangda Li, Yixue Li, Guandu Li, Junfeng Li, Xin-Chang Li, Jieming Li, Yue-Ying Li, Kongdong Li, Chunhui Li, Peiyu Li, Tongyao Li, Lian Li, Linfeng Li, Yuzhe Li, Xinmiao Li, Chenyang Li, Jiacheng Li, Chang-Yan Li, Xiaohua Li, Qifang Li, Vivian Li, Duanxiang Li, Xiaolin Li, Justin Li, Meiting Li, Xue-Er Li, Zhuangzhuang Li, Xiaohui Li, Hongchang Li, Cang Li, Xuepeng Li, Youwei Li, Mingjiang Li, Ronggui Li, Xingwang Li, Tiange Li, Yongjia Li, Dacheng Li, Xinmin Li, Zongyu Li, Luquan Li, Guoxing Li, Shujie Li, Jianyong Li, Zongchao Li, Yanbin Li, Jia Li, Shiliang Li, Haimin Li, Qinrui Li, Sheng-Qing Li, Yiming Li, Lingjie Li, Xiao-Tong Li, Yiwen Li, Tie Li, Baoqi Li, Wei-Bo Li, Leyao Li, Xiaoyi Li, Liyan Li, Xiao-Qin Li, Xiaokun Li, Xinke Li, Ming-Wei Li, Wenfeng Li, Minzhe Li, Jiajing Li, Karen Li, Yanlin Li, X Li, Liao-Yuan Li, Meifang Li, Yanjing Li, Yongkai Li, Maosheng Li, Ju-Rong Li, Jin Li, Shibo Li, Hangwen Li, Li-Na Li, Hengguo Li, An-Qi Li, Xuehua Li, AnHai Li, Hui Li, Chenli Li, Rumei Li, Zhengrui Li, Fangqi Li, Xiaoguang Li, Xian Li, Danjie Li, Yan-Yu Li, Vivian S W Li, Qinghua Li, Lipeng Li, Qinqin Li, Leilei Li, Defu Li, Ranchang Li, Lianyong Li, Amy Li, Zhou Li, Q Li, Haoyu Li, Xiaoyao Li, M-J Li, Jiao-Jiao Li, Rongling Li, Zhu Li, Tong-Ruei Li, Bizhi Li, Cheng-Wei Li, Wenwen Li, Guangqiang Li, Jian'an Li, Ben Li, Sichong Li, Wenyi Li, Yingxia Li, Meiyan Li, Qing-Min Li, Yonghe Li, Yun-Da Li, Xinwei Li, Shunhua Li, Yu-I Li, Mingxi Li, Jian-Qiang Li, Yingrui Li, Chenfeng Li, Qionghua Li, Guo-Li Li, Xingchen Li, Ziqi Li, Shen Li, Tianjiao Li, Gui-Rong Li, Shufen Li, Yunfeng Li, Yunpeng Li, Yueqi Li, Qiong Li, Xiao-Guang Li, Jiali Li, Zhencheng Li, Qiufeng Li, Songyu Li, Xu Li, Pinghua Li, Shi-Fang Li, Shude Li, Zhibin Li, Yaxiong Li, Zhenli Li, Qing-Fang Li, Rosa J W Li, Yunxiao Li, Hsin-Yun Li, Shengwen Li, Gui-Bo Li, XiaoQiu Li, Xueer Li, Zhi Li, Zhankui Li, Zihai Li, Yue-Jia Li, Haihong Li, Peifen Li, Taixu Li, Mingzhou Li, Jiejing Li, Meng-Miao Li, Meiying Li, Chunlian Li, Meng Li, Zhijie Li, Cun Li, Huimin Li, Ruifang Li, T Li, Xiao-xu Li, Man-Xiang Li, Yinghui Li, Cong Li, Chengbin Li, Feilong Li, Yuping Li, Sin-Lun Li, Weiling Li, Mengfan Li, Jie Li, Shiyan Li, Lianbing Li, G Li, Yanchun Li, Xuze Li, Zhi-Yong Li, Yukun Li, Wenjian Li, Jialin Li, He Li, Bichun Li, Xiong Bing Li, Hanqin Li, Qingjie Li, Wen Lan Li, Guoge Li, Han Li, Wen-Wen Li, Keying Li, Yutang Li, Minze Li, Xingcheng Li, Wanshun Li, Congxin Li, Hankun Li, Hongling Li, Xiangrui Li, Chaojie Li, Michelle Li, Caolong Li, Zhifan Li, J Li, Zhi-Jian Li, Jianwei Li, Yan-Guang Li, Jiexin Li, Hongyan Li, Ji-Min Li, Zhen-Xi Li, Guangdi Li, Peipei Li, Tian-Yi Li, Xiaxia Li, Yuefeng Li, Nien Li, Zhihao Li, Peiyuan Li, Yao Li, Zheyun Li, Tiansen Li, Chi-Yuan Li, Xiangfei Li, Xue Li, Zhonglin Li, Fen Li, Lin Li, Jieshou Li, Chenjie Li, Jinfang Li, Roger Li, Yanming Li, Hong-Lan Li, Mengqing Li, Ben-Shang Li, S L Li, Shunqing Li, Ming-Kai Li, Xionghao Li, Lan Li, Menglu Li, Huiqing Li, Yantao Li, Yanwei Li, Chien-Te Li, Wenyan Li, Xiaoheng Li, Zeyuan Li, Yongle Li, Ruolin Li, Hongqin Li, Zhenhao Li, Jonathan Z Li, Haying Li, Shao-Dan Li, Muzi Li, Yong-Liang Li, Gen Li, M Li, Dong-Ling Li, Chenwen Li, Jiehan Li, Yong-Jian Li, Le Li, Hongguo Li, Chenxin Li, Yongsen Li, Qingyun Li, Pengyu Li, Ai-Qin Li, Si-Wei Li, Zichao Li, Manru Li, Caili Li, Yingxi Li, Yuqian Li, Guannan Li, Wei-Dong Li, Cien Li, Qingyu Li, Xijing Li, Jingshang Li, Xingyuan Li, Dehua Li, Wenlong Li, Ya-Feng Li, Yanjiao Li, Jia-Huan Li, Yuna Li, Xudong Li, Guoxi Li, Xingfang Li, Shengli Li, Shugang Li, Jisheng Li, Rongyao Li, Xuan Li, Yongze Li, Ru Li, Yongxin Li, Lu Li, Jiangya Li, Yiche Li, Yilang Li, Zhuo-Rong Li, Bingbing Li, Qinglin Li, Runzhi Li, Yunshen Li, Jingchun Li, Qi-Jing Li, Hexin Li, Yanping Li, Zhenyan Li, H J Li, Ji Xia Li, Yu-Ye Li, Meizi Li, Qing-Wei Li, Qiang Li, Yuezheng Li, Hsiao-Hui Li, L I Li, Zhengnan Li, Jianglong Li, Hongzheng Li, Laiqing Li, Ningyang Li, Zhongxia Li, Guangquan Li, Xiaozheng Li, Hui-Jun Li, Shun Li, Guojun Li, Xuefei Li, Senlin Li, Hung Li, Jinping Li, Sainan Li, Huili Li, Jinghui Li, Zulong Li, Chengsi Li, P Li, Hongzhe K Li, Fulun Li, Xiao-Qiu Li, Jiejia Li, Yonghao Li, Mingli Li, Yehong Li, Zhihui Li, Yi-Yang Li, Fujun Li, Pei Li, Quanshun Li, Yongping Li, Liguo Li, Ni Li, Weimin Li, Mingxia Li, Xue-Hua Li, M V Li, Luxuan Li, Qiang-Ming Li, Yakui Li, Huafu Li, Xinye Li, Gan Li, Shichao Li, Chunliang Li, Ruiyang Li, Dapei Li, Zejian Li, Lihong Li, Chun Li, Jianan Li, Wenfang Li, Haixia Li, Xiangling Li, Sung-Chou Li, Lianhong Li, Jingmei Li, Ao Li, Yitong Li, Siwen Li, Yanlong Li, Cheng Li, Kui Li, Zhao Li, Tiegang Li, Yunxu Li, Shuang-Ling Li, Zhong Li, Xiao-Long Li, Hung-Yuan Li, Xiaofei Li, Xuanfei Li, Zilin Li, Zhang Li, Jianxin Li, Mingqiang Li, H Li, Xiaojiao Li, Dongliang Li, Yinzhen Li, Chenxiao Li, Hongjia Li, Xiao-Jing Li, Li-Min Li, Yunsheng Li, Xiangqi Li, Jian Li, Y H Li, Jia-Peng Li, Daoyuan Li, Baichuan Li, Haibo Li, Wenqi Li, Zhenzhe Li, Jian-Mei Li, Xiao-Jun Li, Kaimi Li, Yan-Hong Li, Peiran Li, Shi Li, Xueling Li, Qiao Li, Yi-Yun Li, Xiao-Cheng Li, Conghui Li, Xiaoxiong Li, Wanni Li, Yike Li, Yihan Li, Chitao Li, Haiyang Li, Jiayu Li, Xiaobai Li, Junsheng Li, Pingping Li, Mingquan Li, Wen-Ya Li, Suran Li, Rongxia Li, Yunlun Li, Yingqin Li, Yuanfang Li, Guoqin Li, Qiner Li, Huiqin Li, Jiafang Li, Shanhang Li, Chunlin Li, Han-Bing Li, Zongzhe Li, Yikang Li, Jisen Li, Si-Yuan Li, Hongmin Li, Caihong Li, Yajing Li, Peng Peng Li, Guanglu Li, Kenli Li, Benyi Li, Yuquan Li, Xiushi Li, Hongzhi Li, Jian-Jun Li, Dongmin Li, Fengyi Li, Yanling Li, Chengxin Li, Juanni Li, Xiaojiaoyang Li, C Li, Jian-Shuang Li, Xinxin Li, You-Mei Li, Yubin Li, Chenglan Li, Dazhi Li, Beixu Li, Yuhong Li, Guiyuan Li, Di Li, Fengqiao Li, Yanbing Li, Suk-Yee Li, Yuanyuan Li, Jufang Li, Shengjie Li, Xiaona Li, Shanyi Li, Hongbo Li, Chih-Chi Li, Xinhui Li, Zecai Li, Qipei Li, Xiaoning Li, Jun Li, Minghua Li, Xiyue Li, Zhuoran Li, Tianchang Li, Hongru Li, Shiqi Li, Mei-Ya Li, Wuyan Li, Mingzhe Li, Yi-Ling Li, Hongjuan Li, Yingjian Li, Zhirong Li, Wang Li, Mingyang Li, Weijun Li, Boyang Li, Senmao Li, Cai Li, Mingjie Li, Ling-Jie Li, Hong-Chun Li, Jingcheng Li, Ivan Li, Yaying Li, Mengshi Li, Liqun Li, Manxia Li, Ya Li, Changxian Li, Dan-Ni Li, Wen-Chao Li, Sunan Li, Zhencong Li, Chunqing Li, Jiong Li, Lai K Li, Yanni Li, Daiyue Li, Bingong Li, Huifang Li, Yongsheng Li, Xiujuan Li, Lingling Li, Chunxue Li, Yunlong Li, Xinhua Li, Jianshuang Li, Juanling Li, Minerva X Li, Xinbin Li, Alexander H Li, Xue-jing Li, Wendeng Li, Ding Li, Yuling Li, Xianlin Li, Yetian Li, Chuangpeng Li, Mingrui Li, Linyan Li, Shengze Li, Yanjun Li, Ming-Yang Li, Jiequn Li, Zhongding Li, Hewei Li, Da-Jin Li, Jiangui Li, Zhengyang Li, Cyril Li, Xinghui Li, Yuefei Li, Xiao-kun Li, Xinyan Li, Yuanhao Li, Xiaoyun Li, Ji-Lin Li, Congcong Li, Ping'an Li, Yushan Li, Juan Li, Huan Li, Weiping Li, Changjiang Li, Chengping Li, G-P Li, He-Zhen Li, Xiaobin Li, Shaoqi Li, Yuehua Li, Yinliang Li, Wen Li, Jinfeng Li, Shiheng Li, Jiangan Li, Weihai Li, Hsiao-Fen Li, Yu-Kun Li, Zhaojin Li, Mengjiao Li, Bingxin Li, Wenjuan Li, Wenyu Li, Meng-Meng Li, Chia-Yang Li, Tianxiang Li, Liangkui Li, Tian-chang Li, Hairong Li, Yahui Li, Su Li, Xi-Xi Li, Wenlei Li, Mei-Lan Li, Wenjun Li, Jiaxin Li, Haiyan Li, Ming D Li, Chenguang Li, Ruyue Li, Xujun Li, Chi-Ming Li, Xiaolian Li, Dandan Li, Yi-Ning Li, Yunan Li, Zechuan Li, Zhijun Li, Sherly X Li, Jiazhou Li, Wanling Li, Ya-Ge Li, Yinyan Li, Qijun Li, Rujia Li, Guangli Li, Lixia Li, Zhiwei Li, Xueshan Li, Yunrui Li, Yuhuang Li, Shanshan Li, Jiangbo Li, Xiaohan Li, Wan-Shan Li, Zhongwen Li, Huijie Li, W W Li, Yalan Li, Yiyang Li, Jing-gao Li, Xuejun Li, Fengxiang Li, Nana Li, Shunwang Li, Chao Li, Yaqing Li, Jingui Li, Bingsheng Li, Yaqiao Li, Huamao Li, Xiankun Li, Jingke Li, Tianyao Li, Xiaowei Li, Junming Li, Jianfang Li, Shubo Li, Qi-Fu Li, Zi-Zhan Li, Hai-Yun Li, Haoran Li, Zhongxian Li, Xiaoliang Li, Xinyuan Li, Maoquan Li, H-J Li, Zhixiong Li, Chumei Li, Shijie Li, Lingyan Li, Zhanquan Li, Wenguo Li, Fangyuan Li, Xuhang Li, Xiaochun Li, Chen-Lu Li, Xinjian Li, Jialun Li, Rui Li, Zilu Li, Xuemin Li, Zezhi Li, Sheng-Fu Li, Xue-Fei Li, Yudong Li, Shanpeng Li, Hongjiang Li, Wei-Na Li, Dong-Run Li, Yunxi Li, Jingyun Li, Xuyi Li, Binghua Li, Hanjun Li, Yunchu Li, Zhengyao Li, Jin-Qiu Li, Qihua Li, Jiaxuan Li, Jinghao Li, Y-Y Li, Xiaofang Li, Tuoping Li, Pengyun Li, Guangjin Li, Xutong Li, Lin-Feng Li, Ranwei Li, Kai Li, Ziqing Li, Wei-Li Li, Keanning Li, Yongjin Li, Shuangxiu Li, Chenhao Li, Ling Li, Weizu Li, Deming Li, Peiqin Li, Xiaodong Li, Nanxing Li, Qihang Li, Jianrong Li, Baoguo Li, Zhehui Li, Chenghao Li, Jiuyi Li, Luyao Li, Chun-Xu Li, Weike Li, Desheng Li, Zhixuan Li, Chuanbao Li, Long-Yan Li, Fuyu Li, Chuzhong Li, M D Li, Lingzhi Li, Yuan-Tao Li, Kening Li, Guilan Li, Wanshi Li, Hengtong Li, Ling-Zhi Li, Yifan Li, Ya-Li Li, Xiao-Sa Li, Songyun Li, Xiaoran Li, Bolun Li, Kunlin Li, Linchuan Li, Jiachen Li, Haibin Li, Shu-Qi Li, Zehua Li, Huangbao Li, Guo-Chun Li, Xinli Li, Mengyuan Li, S Li, Wenqing Li, Wenhua Li, Caiyun Li, Congye Li, Xinrui Li, Dehai Li, Wensheng Li, Jiannan Li, Qingshang Li, Guanbin Li, Hanbin Li, Zhiyi Li, Xing Li, Wanwan Li, Jia Li Li, Zhaoyong Li, SuYun Li, Shiyi Li, Wan-Hong Li, Suchun Li, Mingke Li, Xiaoyuan Li, Huanhuan Li, Yanan Li, Zongfang Li, Yang Li, Jiayan Li, YueQiang Li, Xiangping Li, H-H Li, Jinman Li, BoWen Li, Duoyun Li, Dongdong Li, Yimei Li, Hao Li, Liliang Li, Mengxi Li, Keyuan Li, Zhi-qiang Li, Shaojing Li, S S Li, Yi-Ting Li, Jiangxia Li, Yujie Li, Tong Li, Lihua Li, Yilong Li, Xue-Lian Li, Zhiping Li, Yan-Li Li, Haiming Li, Yansen Li, Gaijie Li, Yuemei Li, Yanli Li, Jingfeng Li, Zhi-Yuan Li, Hai Li, Yuan-Jing Li, Kaibin Li, Xuefeng Li, Xiaohu Li, Wenjie Li, Ruikai Li, Mengjuan Li, Xiao-Hong Li, Yinglin Li, Yaofu Li, Ren-Ke Li, Qiyong Li, Ruixi Li, Yi Li, Baosheng Li, Zhonglian Li, Yujun Li, Mian Li, Dalin Li, Lixi Li, Jin-Xiu Li, Kun Li, Qizhai Li, Jiwen Li, Pengju Li, Peifeng Li, Zhouhua Li, Ai-Jun Li, Qingqin S Li, Honglei Li, Guojin Li, Yueting Li, Xin-Yue Li, Dingchen Li, YaJie Li, Xiaoling Li, Jixuan Li, Yanqing Li, Zijian Li, Zhandong Li, Xuejie Li, Congjiao Li, Peining Li, Meng-Jun Li, Gaizhen Li, Huilin Li, Liang Li, Songtao Li, Fusheng Li, Huafang Li, Dai Li, Meiyue Li, Chenlu Li, Nianyu Li, Keshen Li, Kechun Li, Yuxin Li, Shaoliang Li, X-L Li, Shawn S C Li, Shu-Xin Li, Hong-Zheng Li, Dongye Li, Qun Li, Tianye Li, Cuiguang Li, Zhen Li, Yuan Li, Chunhong Li, F Li, Mengling Li, Kunpeng Li, Jia-Da Li, Zhenghao Li, Chun-Bo Li, Zhantao Li, Baoqing Li, Pu Li, Xinle Li, Xingli Li, Bingkun Li, Nien-Chi Li, Wuguo Li, Bing-Hui Li, Tiewei Li, Rong-Bing Li, Daniel Tian Li, Jingyong Li, Honggang Li, Rong Li, Wei-Yang Li, Shikang Li, Mingkun Li, Binxing Li, Shi-Ying Li, Zixiao Li, Ming Xing Li, Guixin Li, Quanzhang Li, Ming-Xing Li, Marilyn Li, Da-wei Li, Hong-Lian Li, Bei-Bei Li, Shishi Li, Haitong Li, Xiumei Li, Melody M H Li, Yuli Li, Ruibing Li, Qingfang Li, Peibo Li, Qibing Li, Huanjun Li, Heng Li, Wende Li, Chung-Hao Li, Liuzheng Li, Zhanjun Li, Yifei Li, Tianming Li, Chang-Sheng Li, Xiao-Na Li, Tianyou Li, Jipeng Li, Xidan Li, Yixing Li, Chengcheng Li, Yu-Jin Li, Baoting Li, Longxuan Li, Ka Wan Li, Huiyou Li, Shi-Guang Li, Wenxiu Li, Binbin Li, Xinyao Li, Zhuang Li, Gui-xing Li, Yu-Hao Li, Shilin Li, Shunle Li, Niu Li, Siyue Li, Diyan Li, Mengyao Li, Shili Li, Yixuan Li, Shan-Shan Li, Meiqing Li, Zhuanjian Li, Gerard Li, Yuyun Li, Hengyu Li, Zhiqiong Li, Zonglin Li, Yinhao Li, Pik Yi Li, Junying Li, Jingxin Li, Mufan Li, Chun-Lai Li, Defeng Li, Shiya Li, Zu-guo Li, Xin-Zhu Li, Xiao-Jiao Li, Jia-Xin Li, Kuiliang Li, Pindong Li, Hualian Li, Junhong Li, Youchen Li, Li Li, W Y Li, Hanxue Li, Lulu Li, Yi-Heng Li, Xiaoqin Li, L P Li, Runbing Li, Chunmei Li, Mingjun Li, Yuanhua Li, Qiaolian Li, Yanmin Li, Ji-Cheng Li, Jingyi Li, Yuxiang Li, Hao-Fei Li, Haolong Li, Xuanzheng Li, Peng-li Li, Quan Li, Yining Li, Xue-Ying Li, Xiurong Li, Haiyu Li, Huijuan Li, Xu-Zhao Li, Yunze Li, Yanzhong Li, Guohui Li, Kainan Li, Yongzhe Li, Qingfeng Li, Xiaoyan Li, Tianyi Li, Nanlong Li, Ping Li, Xu-Bo Li, Nien-Chen Li, Fangzhou Li, Yue-Chun Li, Jiahui Li, Huiping Li, Kangyuan Li, Biao Li, Yuanchuang Li, Haiying Li, Yunting Li, Xiaoxuan Li, Anyao Li, Hongliang Li, Qing-Chang Li, Hong-Yan Li, Shengbiao Li, Yue-Rui Li, Ruidong Li, Dalei Li, Zongjun Li, Y M Li, Changqing Li, Hanting Li, Dong-Jie Li, Sijie Li, Dengxiong Li, Xiaomin Li, Meilan Li, D C Li, Andrew C Li, Jianye Li, Yi-Shuan J Li, Tinghao Li, Qiuyan Li, Zhouxiang Li, Tingguang Li, Yun-tian Li, Jianliang Li, Xiangyang Li, Guangzhao Li, Yixi Li, Chunjie Li, Shuyu Dan Li, S A Li, Tianfeng Li, Anna Fen-Yau Li, Minghui Li, Jiangfeng Li, Jinjie Li, Liming Li, Jie-Pin Li, Junyi Li, Kaiyi Li, Dongtao Li, Wenqun Li, Fengyuan Li, Guixia Li, Yinan Li, Aoxi Li, Zuo-Lin Li, Chenxi Li, Yuanjing Li, Zhengwei Li, Linqi Li, Bingjue Li, Xixi Li, Binghu Li, Yan-Chun Li, Suiyan Li, Yu-Hang Li, Qiaoqiao Li, Xiaotian Li, Zhenguang Li, Jia-Ru Li, Shuhui Li, Chun-Xiao Li, Shu-Hong Li, Pei-Qin Li, Shuyue Li, Mengying Li, Quan-Zhong Li, Fangyan Li, Tongzheng Li, Yihong Li, Yaxian Li, Duo Li, Dali Li, Zhiming Li, Xuemei Li, Hongxia Li, Yongting Li, Xueting Li, Danyang Li, Zhenjun Li, Ren Li, Tiandong Li, Hongye Li, Lanfang Li, Di-Jie Li, Mingwei Li, Bo Li, Jinliang Li, Wenxin Li, Qiji Li, W J Li, Zhijia Li, Zhipeng Li, Xiaoping Li, Jingtong Li, Linhong Li, Taoyingnan Li, Lucy Li, Lieyou Li, Zhengpeng Li, Xiayu Li, Huabin Li, Mao Li, Baolin Li, Cuilan Li, Yuting Li, Yongchao Li, Xiaobo Li, Xiaoting Li, Ruotai Li, Meijia Li, Shujiao Li, Yaojia Li, Xiao-Yao Li, Weirong Li, Kun-Ping Li, Weihua Li, Shangming Li, Yaqi Li, Yibo Li, Gui-Hua Li, Zhihong Li, Yandong Li, Runzhao Li, Chaowei Li, Xiang-Dong Li, Huiyuan Li, Yuchun Li, Yanxin Li, Yingjun Li, Xiufeng Li, Xiaohuan Li, Ying-Qin Li, Boya Li, Lamei Li, O Li, Fan Li, Joyce Li, Jun Z Li, Suheng Li, Yiheng Li, Taiwen Li, Hui-Ping Li, Xiaorong Li, Zhiqiang Li, Junru Li, Hecheng Li, Jiangchao Li, Changkai Li, Yueping Li, Haifeng Li, Liping Li, Rena Li, Jiangtao Li, Yu-Jui Li, Zhenglong Li, Yajuan Li, Rui-Jún Eveline Li, Xuanxuan Li, Bing-Mei Li, Chaoqian Li, Yunman Li, Shuhua Li, Yu-Cheng Li, Yirun Li, Chunying Li, Haomiao Li, Leipeng Li, Weiheng Li, Qianqian Li, Baizhou Li, YiQing Li, Zhengliang Li, Han-Ru Li, Wei-Qin Li, Weijie Li, Sheng Li, Guoyin Li, Yaqiang Li, Qingxian Li, Zongyi Li, Dan-Dan Li, Yeshan Li, Qiwei Li, Zirui Li, Yongpeng Li, Chengjun Li, Keke Li, Jianbin Li, Chanyuan Li, Shiying Li, Jianxiong Li, Huaying Li, Ji Li, Tuojian Li, Yixin Li, Ziyue Li, Zhongzhe Li, Juntong Li, Xiang Li, Yumei Li, Xiang-Ping Li, Chaonan Li, Wenqiang Li, Yu-Chia Li, Pei-Shan Li, Zaibo Li, Shaomin Li, Heying Li, Guangming Li, Xuan-Ling Li, Yuxuan Li, Bingshan Li, Xiaoqiang Li, Jiahao Li, Hanxiao Li, Jiansheng Li, Shuying Li, Shibao Li, Kunlong Li, Pengjie Li, Xiaomei Li, Ruijin Li
articles
Biren Dave, Mikayla Machado, Robert Siddaway +13 more · 2025 · JCO precision oncology · added 2026-04-24
CNS tumors are a significant cause of death in the adolescent and young adult (AYA; age 15-39 years) population; however, these patients often lack standardized treatments. In Canada, we have establis Show more
CNS tumors are a significant cause of death in the adolescent and young adult (AYA; age 15-39 years) population; however, these patients often lack standardized treatments. In Canada, we have established national multidisciplinary virtual AYA CNS tumor board rounds (national rounds) to improve and standardize care. From November 2021 to June 2024, 185 AYA patients with CNS tumors were presented from centers nationwide, including 138 patients with glioma. Before case presentation, 5.1% of patients with glioma were taking targeted agents or were enrolled in clinical trials. However, after national rounds, 72.6% of patients with pediatric-type glioma and 45.9% of patients with adult-type glioma were recommended clinical trials and/or targeted agents. Among the 44 patients with glioma who had received radiation therapy before national rounds, only 14 were recommended further radiation. Cumulatively, 68.9% of patients analyzed received a treatment recommendation that represented a change in clinical management compared with their previous treatments. Concurrently, we performed molecular review of 174 AYA CNS tumors during the study time frame. Using TruSight, we identified gene fusions involving Our results suggest that national rounds with centralized molecular review can direct AYA patients with CNS tumors toward targeted agents and clinical trials, while deferring radiation therapy. Taken together, our work details an ongoing effort to improve and standardize care of AYA patients with CNS tumors in Canada. Show less
📄 PDF DOI: 10.1200/PO-25-00557
FGFR1
Wan Peng, Gao-Fei Li, Guo-Wang Lin +11 more · 2025 · Oncogene · Nature · added 2026-04-24
Hereditary multiple exostoses (HME) is an autosomal dominant skeletal disorder primarily linked with mutations in Exostosin-1 (EXT1) and Exostosin-2 (EXT2) genes. However, not all HME cases can be exp Show more
Hereditary multiple exostoses (HME) is an autosomal dominant skeletal disorder primarily linked with mutations in Exostosin-1 (EXT1) and Exostosin-2 (EXT2) genes. However, not all HME cases can be explained by these mutations, and its pathogenic mechanisms are not fully understood. Herein, utilizing whole-exome sequencing and genetic screening with a family trio design, we identify two novel rare mutations co-segregating with HME in a Chinese family, including a nonsense mutation (c.204G>A, p.Trp68*) in EXT1 and a missense mutation (c.893T>G, p.Phe298Cys) in FUT7. Functional assays reveal that the FUT7 mutation affects the cellular localization of FUT7 protein and regulates cell proliferation. Notably, the simultaneous loss of fut7 and ext1 in a zebrafish model results in severe chondrodysplasia, indicating a functional link between FUT7 and EXT1 in chondrocyte regulation. Additionally, we unveil that FUT7 p.Phe298Cys reduces EXT1 expression through IL6/STAT3/SLUG axis at the transcription level and through ubiquitination-related proteasomal degradation at the protein level. Together, our findings not only identify novel germline mutations in FUT7 and EXT1 genes, but also highlight the critical interaction between these genes, suggesting a potential 'second-hit' mechanism over EXT1 mutations in HME pathogenesis. This insight enhances our understanding of the mechanisms underlying HME and opens new avenues for potential therapeutic interventions. Show less
📄 PDF DOI: 10.1038/s41388-024-03254-3
EXT1
Hua-Xiong Zhang, Dilmurat Hamit, Qing Li +6 more · 2025 · Scientific reports · Nature · added 2026-04-24
Melatonin (MLT) can improve mitophagy, thereby ameliorating cognitive deficits in Alzheimer's disease (AD) patients. Hence, our research focused on the potential value of MLT-related genes (MRGs) in A Show more
Melatonin (MLT) can improve mitophagy, thereby ameliorating cognitive deficits in Alzheimer's disease (AD) patients. Hence, our research focused on the potential value of MLT-related genes (MRGs) in AD through bioinformatic analysis. First, the key cells in the single-cell dataset GSE138852 were screened out based on the proportion of annotated cells and Fisher's test between the AD and control groups. The differentially expressed genes (DEGs) in the key cell and GSE5281 datasets were identified, and the MRGs in GSE5281 were selected via weighted gene coexpression network analysis. After intersecting two sets of DEGs and MRGs, we performed Mendelian randomization analysis to identify the MRGs causally related to AD. Biomarkers were further ascertained through receiver operating characteristic curve (ROC) and expression analysis in GSE5281 and GSE48350. Furthermore, gene set enrichment analysis, immune infiltration analysis and correlation analysis with metabolic pathways were conducted, as well as construction of a regulator network and molecular docking. According to the Fisher test, oligodendrocytes were regarded as key cells due to their excellent abundance in the GSE138852 dataset, in which there were 281 DEGs between the AD and control groups. After overlapping with 3,490 DEGs and 550 MRGs in GSE5281, four genes were found to be causally related to AD, namely, G protein-coupled receptor, family C, group 5, member B (GPRC5B), Methyltransferase-like protein 7 A (METTL7A), NF-κB inhibitor alpha (NFKBIA) and RAS association domain family 4(RASSF4). Moreover, GPRC5B, NFKBIA and RASSF4 were deemed biomarkers, except for METTL7A, because of their indistinctive expression between the AD and control groups. Biomarkers might be involved in oxidative phosphorylation, adipogenesis and heme metabolism. Moreover, T helper type 17 cells, natural killer cells and CD56dim natural killer cells were significantly correlated with biomarkers. Transcription factors (GATA2, POU2F2, NFKB1, etc.) can regulate the expression of biomarkers. Finally, we discovered that all biomarkers could bind to MLT with a strong binding energy. Our study identified three novel biomarkers related to MLT for AD, namely, GPRC5B, NFKBIA and RASSF4, providing a novel approach for the investigation and treatment of AD patients. Show less
📄 PDF DOI: 10.1038/s41598-024-80755-x
GPRC5B
Yanping Wang, Xiaoru Ma, Zhixin Qiao +16 more · 2025 · Journal of neuroinflammation · BioMed Central · added 2026-04-24
Astrocytes are key regulators of neuroinflammation in multiple sclerosis (MS). Electroacupuncture (EA), a safe and cost-effective adjuvant therapy, has shown benefits in neurodegenerative diseases, bu Show more
Astrocytes are key regulators of neuroinflammation in multiple sclerosis (MS). Electroacupuncture (EA), a safe and cost-effective adjuvant therapy, has shown benefits in neurodegenerative diseases, but its astrocyte-related mechanisms remain unclear. Here, we demonstrated that EA at ST36 alleviated blood-brain barrier (BBB) disruption and neuroinflammation during the peak period of experimental autoimmune encephalomyelitis (EAE). Additionally, EA at ST36 upregulated the expression of α-melanocyte-stimulating hormone (α-MSH) and its receptor melanocortin-4 receptor (MC4R) in spinal astrocytes. Pharmacological studies showed that MC4R agonist RO27-3225 mimicked the therapeutic effects of EA, whereas MC4R antagonist TCMCB07 weakened EA-mediated BBB protection and neuroinflammation suppression. Moreover, astrocyte-specific silencing of MC4R via adeno-associated virus (AAV) weakened EA-mediated BBB protection and neuroinflammation suppression. RNA-sequencing (RNA-seq) and western blot (WB) revealed that EA exerts neuroprotective effects by activating MC4R to inhibit MAPK and NF-κB signaling pathways. Moreover, in MC4R-overexpressing astrocytes, α-MSH and RO27-3225 reduced inflammation responses, while TCMCB07 reversed the effects by MAPK/NF-κB signaling pathways. Collectively, our findings identify astrocytic MC4R as a critical mediator of EA-driven neuroprotection by suppressing MAPK/NF-κB signaling, providing mechanistic insight and a promising therapeutic target for EAE and other neuroinflammatory disorders. Show less
📄 PDF DOI: 10.1186/s12974-025-03667-1
MC4R
Jingshu Li, Xuanyi Du, Rui Zhang +7 more · 2025 · Scientific reports · Nature · added 2026-04-24
End-stage renal disease (ESRD) is associated with high morbidity and mortality. Identifying patients with stage 4 chronic kidney disease (CKD) at risk of short-term progression to ESRD remains challen Show more
End-stage renal disease (ESRD) is associated with high morbidity and mortality. Identifying patients with stage 4 chronic kidney disease (CKD) at risk of short-term progression to ESRD remains challenging. Accurate prediction can improve advanced care planning and patient outcomes. This study aimed to develop and validate a machine learning (ML) model for predicting progression within 25 weeks (approximately six months) of ESRD in patients with stage 4 CKD. Electronic health records (EHRs) of patients with stage 4 CKD were analyzed. Nine ML models including Ridge regression (Ridge), random forest (RF), and eXtreme Gradient Boosting (XGBoost) were used to predict short-term progression to ESRD within 25 weeks. The models were trained and externally validated using the data of 346 and 105 patients. Of the 451 patients with stage 4 CKD, 219 developed ESRD. Among the evaluated models, XGBoost demonstrated the best overall performance. In the internal validation, it achieved an area under the curve (AUC) of 0.93, an accuracy of 0.90, and an F1 score of 0.89. In the external validation, XGBoost maintained the highest AUC (0.85), accuracy (0.79), and F1 score (0.79), along with the highest average precision (0.89) and a low log-loss (0.48), indicating strong discriminative ability and good generalizability. The top predictive features included high-density lipoprotein cholesterol, Alb, Cys C, ApoB, FGB, Bun, Neutrophil, and Total cholesterol. This study demonstrated the feasibility of ML for assessing ESRD prognosis based on easily accessible clinical features. XGBoost demonstrated superior performance in both internal and external validation, suggesting its potential for future patient screening. Show less
📄 PDF DOI: 10.1038/s41598-025-23037-4
APOB
Jingru Wang, Bo Yao, Yutian Zhang +13 more · 2025 · Journal of nanobiotechnology · BioMed Central · added 2026-04-24
Macrophage-like phenotype switching of vascular smooth muscle cells (VSMCs) is a crucial mechanism driving atherogenesis. Inhibition of a phenotype switch to macrophage-like cells is a promising strat Show more
Macrophage-like phenotype switching of vascular smooth muscle cells (VSMCs) is a crucial mechanism driving atherogenesis. Inhibition of a phenotype switch to macrophage-like cells is a promising strategy to prevent atherosclerosis (AS), and targeted nanotherapeutics represent one approach for implementing this strategy. To this end, we designed immunosuppressive oligodeoxynucleotide A151 functionalized selenium nanoparticles with a spearhead LacNAc (LN-A151-SeNPs) that target macrophage-like VSMCs. Nano characterization showed that the uniformity and stability of nanoparticles were optimized by modification with LacNAc and A151, resulting in an average diameter of 88.90 ± 1.45 nm, Zeta potentials of -21.1 ± 1.5 mV, a A151:Se molar ratio of 1:60 and mass ratio of 1.68:1. The effects of LN-A151-SeNPs on inhibiting VSMCs phenotype switching and attenuation of AS were investigated using [Image: see text] The online version contains supplementary material available at 10.1186/s12951-025-03925-7. Show less
📄 PDF DOI: 10.1186/s12951-025-03925-7
APOE
Yulong Fu, Canran Gao, Hailing Zhang +7 more · 2025 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Wiley · added 2026-04-24
Injectable hydrogel implants represent a promising therapeutic approach for ischemic heart failure; but their efficacy is often limited by low bioactivity, poor durability, and inadequate injection te Show more
Injectable hydrogel implants represent a promising therapeutic approach for ischemic heart failure; but their efficacy is often limited by low bioactivity, poor durability, and inadequate injection techniques. Herein, a unique hydrogel incorporating extracellular matrix from fish swim bladder (FSB-ECM), which has distinct advantages over mammalian derived ECM, such as low antigenicity, bioactivity, and source safety, is developed. It consists of collagen, glycoproteins, and proteoglycans, including 13 proteins common in the myocardial matrix and three specific proteins: HSPG, Col12a1, and vWF. This hydrogel enhances cardiac cell adhesion and stretching while promoting angiogenesis and M2 macrophage polarization. In addition, its storage modulus (G') increases over time, reaching about 1000 Pa after 5 min, which facilitates transcatheter delivery and in situ gelling. Furthermore, this hydrogel provides sustained support for cardiac contractions, exhibiting superior longevity. In a rat model of ischemic heart failure, the ejection fraction significantly improves with FSB-ECM treatment, accompanied by increased angiogenesis, reduced inflammation, and decreased infarct size. Finally, RNA sequencing combined with in vitro assays identifies ANGPTL4 as a key protein involved in mediating the effects of FSB-ECM treatment. Overall, this new injectable hydrogel based on FSB-ECM is suitable for transcatheter delivery and possesses remarkable reparative capabilities for treating heart failure. Show less
📄 PDF DOI: 10.1002/advs.202500036
ANGPTL4
Song Luo, Xiaorui Wang, Bo Ma +12 more · 2025 · Biomolecules & biomedicine · added 2026-04-24
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective death of motor neurons in the spinal cord, brainstem, and motor cortex. This study investigates the ef Show more
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective death of motor neurons in the spinal cord, brainstem, and motor cortex. This study investigates the effects of simvastatin on the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. The experiment included three groups: C57BL/6 wild-type mice, C57BL/6J SOD1G93A mice treated with PBS (SOD1G93A + PBS), and C57BL/6J SOD1G93A mice treated with simvastatin (SOD1G93A + simvastatin). The primary endpoints were survival rates, body weight changes, performance in pole climbing and suspension tests, and neurological deficit scores. Pathological changes were assessed using hematoxylin and eosin staining, transmission electron microscopy, Nissl staining, and Masson staining. Proteomic and metabolomic analyses were performed to identify differentially expressed proteins (DEPs) and metabolites. Quantitative real-time polymerase chain reaction and western blotting were used to measure gene expression. Although there were no significant differences in survival rates, body weight, pole climbing, and suspension test performance, or neurological deficit scores between the SOD1G93A + simvastatin and SOD1G93A + PBS groups, simvastatin treatment improved axonal organization within the spinal cord, increased the number of neurons, and reduced cytoplasmic swelling and gastrocnemius fibrosis. A total of 47 DEPs and 13 differential metabolites were identified between the SOD1G93A + PBS and SOD1G93A + simvastatin groups. Notably, the expression levels of Apoa4 and Alb were elevated in the SOD1G93A + simvastatin group compared to the SOD1G93A + PBS group. Our results suggest that simvastatin may have potential therapeutic effects in ALS, likely involving the modulation of Apoa4 and Alb expression. Show less
📄 PDF DOI: 10.17305/bb.2024.11218
APOA4
Sotirios Tsimikas, Henry N Ginsberg, Veronica J Alexander +5 more · 2025 · Journal of clinical lipidology · Elsevier · added 2026-04-24
Familial chylomicronemia syndrome (FCS) is diagnosed by genetic or nongenetic criteria. To assess responses to treatment of apolipoprotein (apo)C-III, triglycerides, and pancreatitis events in patient Show more
Familial chylomicronemia syndrome (FCS) is diagnosed by genetic or nongenetic criteria. To assess responses to treatment of apolipoprotein (apo)C-III, triglycerides, and pancreatitis events in patients with FCS-based diagnostic methods. APPROACH enrolled 66 patients with FCS randomized to volanesorsen or placebo for 12 months. In 50 participants, genetic confirmation of FCS was based on the presence of pathogenic bi-allelic variants in LPL, APOC2, APOA5, GPIHBP1, or LMF1 genes. In 16 participants without a genetic diagnosis, FCS was diagnosed using clinical criteria and postheparin lipoprotein lipase activity ≤20% of normal. Plasma levels of apoC-III, triglycerides and related variables were measured at 3, 6, and 12 months. No significant differences were present in mean apoC-III reductions with volanesorsen at 3, 6, or 12 months in patients with FCS diagnosed either genetically or nongenetically. In contrast, the triglyceride reductions were statistically less robust in patients with genetic diagnosis at each timepoint, with mean (95% CI) percent reduction in triglycerides of -68.7% (-78.7, -58.6) vs -84.0% (-99.4, -68.6), P = .014 at Month 3; -58.2% (-78.1, -38.2) vs -84.5% (-122.4, -46.7), P = .009 at Month 6; and -35.6% (-57.7, -13.4) vs. -69.0% (-105.0, -33.1), P = .005 at Month 12. Patients with a genetic diagnosis had significantly lower response rates for achieved triglycerides <500 mg/dL, <750 mg/dL, <880 mg/dL and <1000 mg/dL than patients with a nongenetic diagnosis. All 5 episodes of acute pancreatitis occurred in patients with a genetic diagnosis. For a similar reduction in apoC-III in response to volanesorsen, triglyceride reduction is attenuated in patients with genetically vs nongenetically diagnosed FCS. Show less
no PDF DOI: 10.1016/j.jacl.2024.12.018
APOA5
Yushan Zhou, Yuxuan Zhang, Yanli Li +3 more · 2025 · In vitro cellular & developmental biology. Animal · Springer · added 2026-04-24
Interleukin-27 (IL-27) is a cytokine that is reported to be highly expressed in the peripheral blood of patients with pulmonary tuberculosis (PTB). IL-27-mediated signaling pathways, which exhibit ant Show more
Interleukin-27 (IL-27) is a cytokine that is reported to be highly expressed in the peripheral blood of patients with pulmonary tuberculosis (PTB). IL-27-mediated signaling pathways, which exhibit anti- Mycobacterium tuberculosis (Mtb) properties, have also been demonstrated in macrophages infected with Mtb. However, the exact mechanism remains unclear. This study aimed to clarify the potential molecular mechanisms through which IL-27 enhances macrophage resistance to Mtb infection. Both normal and PTB patients provided bronchoalveolar lavage fluid (BALF). Peripheral blood mononuclear cells (PBMCs) were isolated from healthy individuals and stimulated with 50 ng/mL macrophage-colony stimulating factor (M-CSF) to obtain monocyte-derived macrophages (MDMs). Using 100 ng/mL phorbol 12-myristate 13-acetate (PMA), THP-1 cells were induced to differentiate into THP-1-derived macrophage-like cells (TDMs). Both MDMs and TDMs were subsequently infected with the Mtb strain H37Rv and treated with 50 ng/mL IL-27 prior to infection. The damage and inflammation of macrophages were examined using flow cytometry, enzyme-linked immunosorbent assay (ELISA), and Western blotting. Patients with PTB had elevated levels of IL-27 in their BALF. Preconditioning with IL-27 was shown to reduce H37Rv-induced MDMs and TDMs apoptosis while also decreasing the levels of Cleaved Caspase-3, Bax and the proinflammatory cytokines TNF-α, IL-1β, and IL-6, promoting the expression of Bcl-2 and the anti-inflammatory factors IL-10 and IL-4. Silencing of the IL-27 receptor IL-27Ra increased macrophage damage and inflammation triggered by H37Rv. Mechanistically, IL-27 activates autophagy by inhibiting TLR4/NF-κB signaling and activating the PI3K/AKT signaling pathway, thereby inhibiting H37Rv-induced macrophage apoptosis and the inflammatory response. Our study suggests that IL-27 alleviates H37Rv-induced macrophage injury and the inflammatory response by activating autophagy and that IL-27 may be a new target for the treatment of PTB. Show less
📄 PDF DOI: 10.1007/s11626-024-00989-x
IL27
Fiza Javed, Robert A Hegele, Abhimanyu Garg +6 more · 2025 · Journal of clinical lipidology · Elsevier · added 2026-04-24
Familial chylomicronemia syndrome (FCS) is a rare Mendelian autosomal recessive disorder (MIM 238600) characterized by extreme and sustained hypertriglyceridemia due to profound reduction of lipoprote Show more
Familial chylomicronemia syndrome (FCS) is a rare Mendelian autosomal recessive disorder (MIM 238600) characterized by extreme and sustained hypertriglyceridemia due to profound reduction of lipoprotein lipase (LPL) activity. This expert opinion statement synthesizes current knowledge on the definition, pathophysiology, genetics, prevalence, diagnosis, and management of FCS. FCS typically manifests at a young age with persistent severe hypertriglyceridemia-defined as ≥10 mmol/L (≥885 mg/dL), or ≥1000 mg/dL (≥11.2 mmol/L) depending on region and whether Systeme International (SI) units are utilized-in the absence of secondary factors, resistance to conventional lipid-lowering therapies, and a high lifetime risk of acute pancreatitis. It is caused by biallelic pathogenic variants in the LPL gene encoding LPL, or 1 of 4 other related genes that encode proteins that interact with LPL. Affected individuals require a strict, lifelong very low-fat diet with <15% of energy from fat. Emerging therapies inhibiting apolipoprotein C-III show promise in reducing serum triglycerides and pancreatitis risk in patients with FCS. A multidisciplinary approach, encompassing dietary management, pharmacotherapy, and patient education, is pivotal in mitigating the significant morbidity associated with FCS. Show less
no PDF DOI: 10.1016/j.jacl.2025.03.013
LPL
Xinyue Yang, Shufen Li, Yuqing Feng +3 more · 2025 · Carbohydrate polymers · Elsevier · added 2026-04-24
Metabolic associated fatty liver disease (MAFLD) is a globally recognized chronic metabolic disorder characterized by lipid metabolism abnormalities. Accumulating evidence indicates that exopolysaccha Show more
Metabolic associated fatty liver disease (MAFLD) is a globally recognized chronic metabolic disorder characterized by lipid metabolism abnormalities. Accumulating evidence indicates that exopolysaccharides (EPS) could modulate the gut microbiota structure and function to prevent and treat MAFLD. Herein, a novel EPS designated BVP1 was isolated from Bacillus velezensis CGMCC 24752. Structural analysis revealed that BVP1 is a neutral α-mannan consisting of a backbone of 1,2,6-linked α-D-Manp, with branches composed of T-linked α-D-Manp, 1,2-linked α-D-Manp, and 1,3-linked α-D-Manp. Animal experiments showed that BVP1 significantly alleviated hepatic steatosis, liver injury and inflammation, and enhanced antioxidant activity in MAFLD mice. Single-nucleus RNA sequencing analysis revealed that BVP1 could restore HFD-induced imbalances in liver sinusoidal endothelial cells, hepatic stellate cells, macrophages and Kupffer cells by upregulating the expression of the lipid degradation gene Cps1 and downregulating the expression of the lipid synthesis gene Acsl1 in these cell subpopulations. Interestingly, BVP1 reshaped the gut microbiota and fecal metabolite profile by enriching beneficial bacteria and associated metabolites including salicylic acid, spermidine, and 4-hydroxyphenyl acetate. Fecal microbiota transplantation experiments verified that the anti-MAFLD effects are mediated by the BVP1-modified gut microbiota. Our findings highlight the potential of BVP1 as a promising therapeutic agent for MAFLD treatment. Show less
no PDF DOI: 10.1016/j.carbpol.2025.124150
CPS1
Xiaolan Chen, Jin You, Qin Ma +7 more · 2025 · Nature communications · Nature · added 2026-04-24
R-loop is a common chromatin feature consisting of a displaced single-stranded DNA and an RNA-DNA hybrid, and dysregulation of R-loop surveillance results in genomic and transcriptomic instability. Al Show more
R-loop is a common chromatin feature consisting of a displaced single-stranded DNA and an RNA-DNA hybrid, and dysregulation of R-loop surveillance results in genomic and transcriptomic instability. Although the RNA moiety of most R-loops originates from linear transcripts, circular RNAs (circRNAs), outputs from back-splicing, can also hybridize with the complementary strand of a DNA duplex. However, how circRNA-associated R-loops (ciR-loops) are monitored remains elusive. Here, we identify the DEAD-box RNA helicase Brr2 as an evolutionarily-conserved ciR-loop repressor with dual roles in inhibiting circRNA generation and resolving harmful ciR-loops. Accumulation of ciR-loops caused by loss-of-function of this dual-action factor induces antisense transcription and premature transcription termination for many genes and generates significant DNA damage, which further leads to a series of defects in DNA replication, cell division and cell proliferation. We propose that functional integration of multilayered regulation by a single protein can be an efficient double protection against genome instability. Show less
📄 PDF DOI: 10.1038/s41467-025-64174-8
DHX36
Jiahao Li, Yufeng Tang, Guangping Lu +7 more · 2025 · Journal of advanced research · Elsevier · added 2026-04-24
Lipid metabolism disorders have been confirmed to be closely related to kidney injury caused by adriamycin (ADR) and obesity, respectively. However, it has not been explored whether lipid metabolism d Show more
Lipid metabolism disorders have been confirmed to be closely related to kidney injury caused by adriamycin (ADR) and obesity, respectively. However, it has not been explored whether lipid metabolism disorders appear progressively more severe after ADR-based chemotherapy in the obese state, and the specific molecular mechanism needs to be further clarified. This study was designed to examine the role of p53-fibroblast growth factor 21 (FGF21) axis in ADR-induced renal injury aggravated by high-fat diet (HFD). We engineered Fgf21 KO mice and used long-term (4 months) and short-term (0.5 months) HFD feeding, and ADR-injected mice, as well as STZ-induced type 1 diabetic mice and type 2 (db/db) diabetic mice to produce an in vivo model of nephrotoxicity. The specific effects of p53/FGF21 on the regulation of lipid metabolism disorders and its downstream mediators in kidney were subsequently elucidated using a combination of functional and pathological analysis, RNA-sequencing, molecular biology, and in vitro approaches. Long-term HFD feeding mice exhibited compromised effects of FGF21 on alleviation of renal dysfunction and lipid accumulation following ADR administration. However, these impairments were reversed by p53 inhibitor (pifithrin-α, PFT-α). PFT-α sensitized FGF21 actions in kidney tissues, while knockout of Fgf21 impaired the protective effects of PFT-α on lipid metabolism. Mechanistically, p53 impaired the renal expression of FGF receptor-1 (FGFR1) and thereby developed gradually into FGF21 resistance via inhibiting hepatocyte nuclear factor 4 alpha (HNF4α)-mediated transcriptional activation of Fgfr1. More importantly, exogenous supplementation of FGF21 or PFT-α could not only alleviate ADR-induced lipid metabolism disorder aggravated by HFD, but also reduce lipid accumulation caused by diabetic nephropathy. Given the difficulties in developing the long-acting recombinant FGF21 analogs for therapeutic applications, sensitizing obesity-impaired FGF21 actions by suppression of p53 might be a therapeutic strategy for maintaining renal metabolic homeostasis during chemotherapy. Show less
📄 PDF DOI: 10.1016/j.jare.2024.07.014
FGFR1
Bayixiati Qianman, Tuomilisi Jiasharete, Ayinazi Badalihan +9 more · 2025 · Journal of proteome research · ACS Publications · added 2026-04-24
Spontaneous Achilles tendon rupture (SATR) predominantly affects middle-aged and elderly individuals with chronic injuries. However, the exact cause and mechanism of SATR remain elusive, and potential Show more
Spontaneous Achilles tendon rupture (SATR) predominantly affects middle-aged and elderly individuals with chronic injuries. However, the exact cause and mechanism of SATR remain elusive, and potential therapeutic intervention or prevention is still insufficient. The present study aimed to uncover the key pathological molecules by using iTRAQ proteomics. The results identified 2432 candidate proteins in SATR patients using iTRAQ proteomic analysis. A total of 307 differentially expressed proteins (DEPs) were identified and linked to 211 KEGG signaling pathways including Coronavirus disease (COVID-19), focal adhesion, and ribosomes. GO enrichment analysis highlighted significant enrichment in processes such as biological adhesion, ossification, lipid (APOA4) processes, and extracellular matrix (ECM) organization (collagen). PPI network analysis identified hub genes such as serum albumin (ALB), fibronectin (FN1), and actin cytoplasmic 1. The WB analysis confirmed that FN1 and the receptor for activated C kinase (RACK1) were downregulated in the SATR tendon. Immunohistochemical staining revealed that collagen I and III were suppressed, while collagen II and APOA4 expression were higher in the SATR pathological tissue ( Show less
no PDF DOI: 10.1021/acs.jproteome.4c00357
APOA4
Shengfeng Deng, Guo Mu, Jun Li +3 more · 2025 · The journal of physiological sciences : JPS · Elsevier · added 2026-04-24
To investigate the mechanisms underlying sevoflurane-induced POCD, C57BL/6 J mice and SH-SY5Y cells were treated with sevoflurane for model establishment. After the treatment with sevoflurane, CCK-8, Show more
To investigate the mechanisms underlying sevoflurane-induced POCD, C57BL/6 J mice and SH-SY5Y cells were treated with sevoflurane for model establishment. After the treatment with sevoflurane, CCK-8, EdU and flow cytometry were employed to detect cell damage. The levels of N6-methyladenosine (m6A), METTL14 and DUSP6 were determined by qPCR and Western blot. The interaction between METTL14 and DUSP6 was analyzed using RIP-qPCR and Me-RIP methodologies. The cognitive function in mice were assessed by water maze test. After sevoflurane treatment, the cell viability, cell proliferation and METTL14 expression were markedly suppressed, while apoptosis was significantly enhanced. METTL14 overexpression elevated the levels of m6A and DUSP6, increased the binding level of METTL14 to DUSP6 mRNA, reducing damage to cells and cognitive dysfunction of mice. Knockdown of DUSP6 negated the beneficial effects observed with METTL14 overexpression. Sevoflurane induced POCD by regulating METTL14/DUSP6 through m6A methylation. Show less
📄 PDF DOI: 10.1016/j.jphyss.2025.100048
DUSP6
Kang-Chih Fan, Szu-Chi Chen, I-Weng Yen +7 more · 2025 · Archives of medical science : AMS · added 2026-04-24
Angiopoietin-like protein 4 (ANGPTL4) is a hepatokine implicated in fat metabolism regulation. Its genetic inactivation has been associated with improved glucose homeostasis, while elevated plasma ANG Show more
Angiopoietin-like protein 4 (ANGPTL4) is a hepatokine implicated in fat metabolism regulation. Its genetic inactivation has been associated with improved glucose homeostasis, while elevated plasma ANGPTL4 levels are observed in diabetic and obese individuals. However, the potential link between ANGPTL4 and diabetes- or obesity-related complications remains uncertain. This study aimed to explore whether plasma ANGPTL4 level could serve as a predictor of cancer mortality, cardiovascular mortality, and all-cause mortality in a community-based cohort. A community-based cohort study was conducted, where fasting plasma ANGPTL4 concentrations were measured at baseline, and vital status was ascertained through linkage with the National Health Insurance Research Database in Taiwan. During a 10.46-year follow-up period, 29 (2.49%) of the 1163 participants died. Subjects within the highest tertile of plasma ANGPTL4 levels exhibited the lowest survival rate. In unadjusted models, plasma ANGPTL4 significantly predicted all-cause mortality, cancer mortality, and cardiovascular or cancer-related mortality. Upon adjustment for confounders including age, sex, smoking, body mass index (BMI), hypertension, diabetes mellitus (DM), and renal function, each standard deviation increase in plasma ANGPTL4 was associated with HRs of 1.35 (95% CI: 1.01-1.80, Plasma ANGPTL4 emerges as a promising biomarker capable of predicting 10-year mortality and enhancing risk prediction beyond established risk factors. Show less
📄 PDF DOI: 10.5114/aoms/189504
ANGPTL4
Mingxuan Guo, Huanxin Zhao, Nannan Song +5 more · 2025 · Fitoterapia · Elsevier · added 2026-04-24
Sepsis-associated acute lung injury (SA-ALI), a critical complication of sepsis, is characterized by immune dysregulation-induced pulmonary dysfunction. Shenmai Injection (SMI) is a standardized herba Show more
Sepsis-associated acute lung injury (SA-ALI), a critical complication of sepsis, is characterized by immune dysregulation-induced pulmonary dysfunction. Shenmai Injection (SMI) is a standardized herbal preparation consisting of Panax ginseng C.A.Mey (Hongshen) and Ophiopogon japonicus (Thunb.) Ker Gawl (Maidong), traditionally used for qi-replenishing, collapse-stabilizing, and lung-moistening therapy. Although clinically utilized in the management of SA-ALI, the specific mechanisms by which it acts against SA-ALI necessitate further investigation. The present study endeavors to comprehensively determine the therapeutic efficacy of SMI against SA-ALI through an integrated approach combining network pharmacology, metabolomics, metagenomic sequencing, and experimental validation. In this study, murine SA-ALI was established using lipopolysaccharide (LPS) and Poly(I:C). Results indicated that SMI administration significantly attenuated pulmonary inflammation, restored blood-gas barrier integrity, reduced serum pro-inflammatory cytokines and suppressed NF-κB pathway activation in SA-ALI mice. Network pharmacology elucidated the multi-targeted mechanism of SMI in modulating steroid hormone biosynthesis. Integrated metabolomics and target analysis revealed that ophiopogonin A/B and luteolin in SMI alleviates metabolic dysregulation by targeting key enzymes, including AKR1C3, HSD17B1/2, and SULT1E1. Metagenomic profiling demonstrated SMI-mediated gut microbiota remodeling, marked by suppression of pathogenic Chlamydiaceae (particularly Chlamydia abortus) and enrichment of commensal Lactobacillaceae. Correlation analysis showed that intestinal androstenedione and androsterone levels during SMI treatment recovery were negatively correlated with Chlamydia abortus abundance. In conclusion, SMI enhances the recovery from sepsis-associated SA-ALI by dual modulation of gut microbial ecology and host metabolic homeostasis, thereby establishing its potential as a multi-mechanistic therapeutic candidate for sepsis-related organ injury. Show less
no PDF DOI: 10.1016/j.fitote.2025.106935
HSD17B12
Yanyan Zhang, Muzi Li, Zongyun Li +6 more · 2025 · Biomolecules · MDPI · added 2026-04-24
This study evaluated the protective effects of naringin (NG) against intestinal injury in 7-day-old piglets infected with porcine epidemic diarrhea virus (PEDV). Eighteen piglets (Duroc × Landrace × L Show more
This study evaluated the protective effects of naringin (NG) against intestinal injury in 7-day-old piglets infected with porcine epidemic diarrhea virus (PEDV). Eighteen piglets (Duroc × Landrace × Large, body weight = 2.58 ± 0.05 kg) were divided into three treatment groups based on similar body weights and equal numbers of males and females: the blank control group (CON group), the PEDV infection group (PEDV group), and the NG intervention + PEDV infection group (NG + PEDV group) ( Show less
📄 PDF DOI: 10.3390/biom16010048
APOA4
Junyu Zhou, Yong Kwan Kim, Chen Li +1 more · 2025 · Computers in biology and medicine · Elsevier · added 2026-04-24
This study aimed to develop and apply a novel computational pipeline combining SELFormer, a transformer architecture-based chemical language model, with advanced deep learning techniques to predict na Show more
This study aimed to develop and apply a novel computational pipeline combining SELFormer, a transformer architecture-based chemical language model, with advanced deep learning techniques to predict natural compounds (NCs) with potential in Alzheimer's disease (AD) treatment. The NCs were identified based on activity related to seven AD-specific genes, including acetylcholinesterase (AChE), amyloid precursor protein (APP), beta-secretase 1 (BACE1), and presenilin-1 (PSEN1). We implemented a computational pipeline using SELFormer and deep learning techniques, conducted optimal clustering and quantitative structure-activity relationship (QSAR) analyses, and performed a uniform manifold approximation and projection (UMAP) to categorize compounds based on bioactivity levels. Molecular docking analysis was carried out on selected compounds. To validate the computational predictions, we conducted in vitro studies using nerve growth factor (NGF)-differentiated PC12 cells. Finally, we mapped the relationships between food sources containing the identified compounds and their target proteins. Optimal clustering analysis revealed five distinct groups of NCs, while QSAR analysis highlighted variations in molecular properties across clusters. The UMAP projection identified 17 highly active NCs (pIC This integrated computational and experimental approach offers a promising framework for identifying potential NCs for AD treatment. The results contribute to exploring effective therapeutic strategies against AD. Show less
no PDF DOI: 10.1016/j.compbiomed.2024.109523
BACE1
Dan Li, Mi Zhou, Xiaomei Song · 2025 · Frontiers in aging · Frontiers · added 2026-04-24
Cognitive decline is prevalent among older adults and may be associated with their daily activity behaviours. However, no studies have examined how cognitive decline affects older adults' activity beh Show more
Cognitive decline is prevalent among older adults and may be associated with their daily activity behaviours. However, no studies have examined how cognitive decline affects older adults' activity behaviours within a 24-h framework. This study investigates the relationship between cognitive function and 24-h activity behaviours in older adults, further exploring whether these associations differ by sex. This study analyses data from the eighth wave of the Survey of Health, Ageing and Retirement in Europe, conducting a cross-sectional analysis of 814 older adults. Cognitive function was assessed using the SHARE-Cog tool, encompassing 10-word immediate recall, 10-word delayed recall, verbal fluency, and self-reported memory. 24-h activity behaviours (moderate-to-vigorous physical activity [MVPA], light physical activity [LPA], sedentary behaviour [SB], and sleep) were objectively measured with thigh-worn accelerometers. Compositional multivariate linear regression models were constructed using compositional data as the response variable, with cognitive function measures as predictors. Higher MVPA was linked to better cognitive outcomes (verbal fluency, 10-word immediate recall, and 10-word delayed recall) while SB and longer sleep related to poorer performance, with these associations being stronger in women (model p ≤ 0.001). Among women, cognitive outcomes were significantly associated with all activity behaviours (p range = 0.010-0.045). Women who self-reported poor memory and scored 0 on the verbal fluency spent approximately 45% of their day in SB, whereas those reporting excellent memory and scoring 60 spent 40.06% (37.18%, 42.86%) and 36.41% (31.53%, 41.10%) of their day sedentary, respectively. In contrast, men's 24-h activity composition did not vary significantly with cognitive function (p range = 0.051-0.845). Older adults with better cognitive function tend to engage in more PA and reduce sedentary and sleep time. This relationship differed by sex, with females' activity behaviours being more sensitive to cognitive function changes. These findings suggest that interventions promoting healthy lifestyles in older adults should account for cognitive function, particularly in females. Show less
📄 PDF DOI: 10.3389/fragi.2025.1686847
LPA
Tianrui Liu, Feixiang Yang, Zhige Wang +7 more · 2025 · Prostate international · Elsevier · added 2026-04-24
The causal relationships between the gut microbiota and prostate cancer, prostatitis, and benign prostatic hyperplasia remain uncertain. We intend to identify the causal connections between the gut mi Show more
The causal relationships between the gut microbiota and prostate cancer, prostatitis, and benign prostatic hyperplasia remain uncertain. We intend to identify the causal connections between the gut microbiota and prostatic diseases and investigate the potential mechanisms involved. A two-sample Mendelian randomization (MR) analysis was conducted to elucidate the impact of 196 gut microbiota on prostatic diseases risk. Reverse MR, linkage disequilibrium regression score (LDSC), and colocalization analyses were performed to strengthen causal evidence. Phenome-wide MR (Phe-MR) analysis was used to evaluate the potential side effects of targeting the detected gut microbiota. We designed a two-step MR study to assess the mediating effects of sex hormones, blood metabolites, and proteins. According to the MR analyses, 31 bacterial taxa were causally associated with prostatic diseases, of which 23 types were newly identified. In addition, Our study represents the first comprehensive exploration of the causal effects of the gut microbiota on prostatic diseases and reveals the mediating effects of sex hormones and blood metabolites on the "gut-prostate axis." Show less
📄 PDF DOI: 10.1016/j.prnil.2024.11.004
FGFR1
Yamin Guo, Xinmiao Wu, Huimin Zhen +5 more · 2025 · Animals : an open access journal from MDPI · MDPI · added 2026-04-24
Our previous investigations identified miR-30a-3p as a differentially expressed miRNA in ovine mammary tissue across sheep breeds with distinct lactation performance and different physiological stages Show more
Our previous investigations identified miR-30a-3p as a differentially expressed miRNA in ovine mammary tissue across sheep breeds with distinct lactation performance and different physiological stages. However, its regulatory mechanisms controlling mammary gland development and lactation remain unexplored. In this study, the effect of miR-30a-3p on the proliferation of ovine mammary epithelial cells (MECs) and the target genes of miR-30a-3p were investigated. The regulatory effects of miR-30a-3p on the expression of the target genes and the content of triglycerides in ovine MECs were also analyzed. The transfection of miR-30a-3p mimic was found to promote cell viability and the number of proliferated ovine MECs using CCK8 and Edu assays. On the contrary, the miR-30a-3p inhibitor showed the opposite results with the miR-30a-3p mimic. These results suggest that miR-30a-3p promotes the proliferation of ovine MECs. The dual luciferase assay revealed that Phosphatase and Tensin Homolog ( Show less
📄 PDF DOI: 10.3390/ani15081180
LPL
Zhengliang Li, Xiaokai Chen, Juan Wang +6 more · 2025 · Frontiers in cardiovascular medicine · Frontiers · added 2026-04-24
To investigate the risk factors associated with coronary heart disease (CHD) in patients with metabolic-associated fatty liver disease (MAFLD) and develop a nomogram prediction model. This study inclu Show more
To investigate the risk factors associated with coronary heart disease (CHD) in patients with metabolic-associated fatty liver disease (MAFLD) and develop a nomogram prediction model. This study included 394 patients with MAFLD who underwent coronary angiography at The Affiliated Hospital of Qingdao University between December 2019 and December 2024. The study cohort was divided in a 7:3 ratio into training and validation sets comprising 277 and 117 cases, respectively. The training group was further divided into the MAFLD-only ( Of the 394 MAFLD cases, 313 had CHD-related complications. Of the 277 patients in the training set, 220 had CHD, and of the 117 patients in the validation set, 93 had CHD. LASSO regression analysis revealed that the following variables were associated with the risk of CHD: sex, lipoprotein(a) (Lp[a]), low-density lipoprotein cholesterol, white blood cell count (WBC), glycated triglyceride-glucose index (TyG), and atherosclerosis index (AIP). Multivariate logistic regression analysis revealed that sex, Lp(a), WBC, TyG, and AIP were independent risk factors for CHD in MAFLD cases. A nomogram was constructed and an ROC curve was plotted, based on which the optimal cutoff value was determined as 0.698. The area under the curve of the nomogram in the training and validation cohorts was 0.860 (95% CI = 0.807-0.913) and 0.843 (95% CI = 0.757-0.929), respectively. Calibration curves for CHD risk probability showed good agreement between the nomogram's predicted probabilities and the observed event rates. DCA demonstrated the net clinical benefit of the constructed nomogram. Sex, Lp(a), WBC, TyG, and AIP emerged as independent risk factors for CHD in patients with MAFLD and the nomogram prediction model constructed using these factors could effectively predict CHD occurrence. Show less
📄 PDF DOI: 10.3389/fcvm.2025.1652321
LPA
Tao Yang, Xiaohu Hu, Fei Cao +15 more · 2025 · Nature · Nature · added 2026-04-24
The mammalian gut harbours trillions of commensal bacteria that interact with their hosts through various bioactive molecules
📄 PDF DOI: 10.1038/s41586-025-08990-4
APOB
Binbin Gong, Xike Mao, Guoxiang Li +4 more · 2025 · European journal of medical research · BioMed Central · added 2026-04-24
The objective of this study was to assess the correlation between the ApoB/ApoA ratio and the recurrence of kidney stones in a Chinese adult population. We collected electronic records of patients wit Show more
The objective of this study was to assess the correlation between the ApoB/ApoA ratio and the recurrence of kidney stones in a Chinese adult population. We collected electronic records of patients with kidney stones who underwent surgical treatment at our hospital from March 2016 to March 2022. These patients were followed up and categorized into groups based on the recurrence of kidney stones. Parameters related to routine blood and biochemical tests, as well as the history of hypertension and diabetes mellitus, were gathered. Multiple imputation was applied for missing data. Subsequently, differences between the recurrence and non-recurrence groups were assessed using the chi-square test, independent samples t test, or Wilcoxon rank sum test. Logistic regression analysis, subgroup analysis, and propensity-matched analysis were conducted to evaluate the relationship between the ApoB/ApoA ratio and kidney stone recurrence. The study included a total of 923 participants aged > 18 years, among whom 296 experienced kidney stone recurrence during the follow-up period. An elevated ApoB/ApoA ratio was identified as a risk factor for kidney stone recurrence (adjusted OR = 2.48, 95% CI 1.04, 5.92). Propensity-matched analyses further supported the association, showing that elevated ApoB/ApoA ratios were linked to a higher risk of renal stone recurrence (OR = 3.37, 95% CI 1.24-9.17). The dose-response curve illustrated a positive linear correlation between the ApoB/ApoA ratio and the risk of kidney stone recurrence. Increased ApoB/ApoA ratios are positively correlated with the risk of kidney stone recurrence. This association remains significant, although a causal relationship cannot be definitively established. Show less
📄 PDF DOI: 10.1186/s40001-025-03396-4
APOB
Lu Shen, Wenqing Zhai, Ping Jiang +6 more · 2025 · American journal of preventive cardiology · Elsevier · added 2026-04-24
Recent researches highlight the interdependence of lipoprotein(a) [Lp(a)] and Lp(a)-associated cardiovascular risk with the background inflammatory burden. This study aimed to investigate whether syst Show more
Recent researches highlight the interdependence of lipoprotein(a) [Lp(a)] and Lp(a)-associated cardiovascular risk with the background inflammatory burden. This study aimed to investigate whether systemic inflammation modulates Lp(a)-associated coronary stenosis in chronic coronary syndromes (CCS). A total of 1513 participants undergoing angiography at a tertiary cardiology center in China were included in our retrospective, cross-sectional study. Participants were categorized into normal, mild, and severe groups based on the Gensini Scores, which quantitatively assess stenosis severity. Multinomial logistic models were calculated according to accompanying systemic inflammation concentration. Participants with elevated Lp(a) levels had a high coronary stenosis risk: fully adjusted model odds ratios (ORs) [95% confidence intervals (CIs)] for the mild vs. normal and severe vs. normal groups were 1.47 (1.11-1.96) and 1.68 (1.21-2.33). Notably, the strongest Lp(a)-coronary stenosis associations after multi-variable adjustment persisted only in low inflammation concentration [systemic inflammation response index (SIRI) < 0.64)] [mild vs. normal, OR 2.03, 95% CI 1.17-3.54, Elevated Lp(a) correlates with coronary stenosis only in low inflammation concentration. Considering systemic inflammation in personalized Lp(a)-lowering therapies is more conducive for CCS managements. Show less
📄 PDF DOI: 10.1016/j.ajpc.2025.101324
LPA
Xiaolei Song, Chenchen Wang, Qin Ding +8 more · 2025 · Journal of controlled release : official journal of the Controlled Release Society · Elsevier · added 2026-04-24
Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder. The vicious circle between amyloid-β peptide (Aβ) overgeneration and microglial dysfunction is an important path Show more
Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder. The vicious circle between amyloid-β peptide (Aβ) overgeneration and microglial dysfunction is an important pathological event that promotes AD progression. However, therapeutic strategies toward only Aβ or microglial modulation still have many problems. Herein, inspired by the Aβ transportation, an Aβ-derived peptide (CKLVFFAED) engineered biomimetic nanodelivery system (MK@PC-R NPs) is reported for realizing BBB penetration and reprogram neuron and microglia in AD lesion sites. This hollow mesoporous Prussian blue-based MK@PC-R NPs carrying curcumin and miRNA-124 can down-regulate β secretase expression, thereby inhibiting Aβ production and reducing Aβ-induced neurotoxicity. Meanwhile, MK@PC-R NPs with excellent antioxidant and anti-inflammatory properties could normalize the microglial phenotype and promote Aβ degradation, providing neuroprotection. As expected, after treatment with MK@PC-R NPs, the Aβ burdens, neuron damages, neuroinflammation, and memory deficits of transgenic AD mice (APP/PS1 mice) are significantly attenuated. Overall, this biomimetic nanodelivery system with anti-Aβ and anti-inflammatory properties provides a promising strategy for the multi-target therapy of early AD. Show less
no PDF DOI: 10.1016/j.jconrel.2024.12.060
BACE1
Nolan Priedigkeit, Beth Harrison, Robert Shue +27 more · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research · added 2026-04-24
Inflammatory breast cancer (IBC) is a rare and clinically distinct form of breast cancer associated with poor outcomes. The biological mechanisms driving IBC remain poorly understood, partly due to li Show more
Inflammatory breast cancer (IBC) is a rare and clinically distinct form of breast cancer associated with poor outcomes. The biological mechanisms driving IBC remain poorly understood, partly due to limited large-scale genomic studies that directly compare IBC with non-IBC cases. We conducted a retrospective analysis of 140 patients with IBC (68 primary tumors and 72 metastatic tumors) and 2,317 patients with non-IBC (700 primary tumors, 65 local recurrences, and 1,552 metastases). We compared clinicopathologic features, single-nucleotide variants, copy-number variants, tumor mutational burden, and exploratory survival outcomes between IBC and non-IBC tumors. The most frequent somatic alterations in IBC were detected in TP53 (72%), ERBB2 (32%), PIK3CA (24%), CCND1 (12%), MYC (9%), FGFR1 (8%), and GATA3 (8%). Multivariate logistic regression revealed a significant enrichment of TP53 single-nucleotide variants in IBC, particularly in HER2+ and hormone receptor-positive disease. Tumor mutational burden did not differ between IBC and non-IBC cases. In HER2+ disease, a pathway analysis revealed an enrichment of NOTCH pathway alterations. TP53, CCND1, and RB1 alterations were associated with poor outcomes in IBC. This study provides a comprehensive resource of somatic alterations in a large cohort of patients with metastatic IBC and non-IBC, highlighting genomic features associated with worse outcomes. Our findings reveal a significant enrichment of TP53 mutations, reinforcing its critical role in IBC pathogenesis. Few other distinct differences in IBC were observed, suggesting further investigations-beyond bulk sequencing of the somatic genome-are required to better understand the biology driving this aggressive disease. Show less
📄 PDF DOI: 10.1158/1078-0432.CCR-24-2081
FGFR1
Zhuan Gao, Yue Li, Yu-Jie Yang +4 more · 2025 · Surgical and radiologic anatomy : SRA · Springer · added 2026-04-24
To clarify the anatomical characteristics of the lateral plantar ligament (LPL) of the transverse metatarsal arch (TMA) in the population of southwest Shandong Province, so as to complement the anatom Show more
To clarify the anatomical characteristics of the lateral plantar ligament (LPL) of the transverse metatarsal arch (TMA) in the population of southwest Shandong Province, so as to complement the anatomical structures of the midfoot and Lisfranc joint complexes. A total of 100 adult lower limbs were dissected and the types of LPL were divided according to their insertions, among them, 63 were (63%) and 37 were female (37%); 50 were on the left side (50%) and 50 were on the right side (50%). The fiber bundle length, origin width, insertion width, and thickness of the LPL were measured. (1) According to the insertions of the LPL, they were divided into: ① Type I, the LPL was inserted at the base of the second metatarsal (M2) in 47 cases; ② Type II, the LPL was inserted at the base of M2 and fused with tibialis posterior tendon (TPT) in 16 cases; ③ Type III, the LPL was absent in 16 cases; ④ Type IV, the LPL was inserted at TPT in 6 cases; ⑤ Type V, the LPL was inserted at the intermediate cuneiform (IC) in 1 case; ⑥ Type VI, bifid LPL with one bundle inserted at the base of M2, and the other bundle inserted at the medial cuneiform (MC) in 4 cases; ⑦ Type VII, two bundles of LPL inserted at the base of M2 in 8 cases; ⑧ Type VIII, the LPL consisted of 3 bundles; the distal, middle and proximal bundles was inserted at the base of M2, the TPT and the lateral side of navicular bone in 2 cases, respectively. (2) There was a statistical significance in the length of LPL between male (31.62 ± 3.83) mm and female (28.07 ± 3.46) mm (t=-3.050, P = 0.003). There was no statistical significance in the types of LPL between male and female (Z=-1.721, P > 0.05), and no statistical significance in the types between left and right sides (Z=-0.026, P > 0.05). According to our research, LPL originates from M5 and is divided into 8 types according to its insertion location, of which insertion at the base of M2 is the most common. In addition, we found that LPL has fibrous fusion with the long plantar ligament and the TPT, which may be involved in maintaining arch stability. The classification of LPL in this study is a supplement to the anatomical structure of the middle foot and Lisfranc joint complex, providing a new direction for the diagnosis and treatment of middle foot and arch injury in the future. Show less
📄 PDF DOI: 10.1007/s00276-025-03651-7
LPL